Drug Trial Radar · NCT07221838
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Mar 4, 2026
Primary completion
Aug 27, 2027
Study completion Aug 27, 2027
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
Conditions
- Generalized Myasthenia Gravis
- gMG
Interventions
Oral Corticosteroid Tapering ScheduleProcedure
During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the participant. The oral corticosteroid (prednisone/prednisolone) is provided as per standard medical care.
RavulizumabDrug
Patients being treated with intravenous ravulizumab as part of their standard medical care.
Prednisone/PrednisoloneDrug
Participants will continue with or be switched to prednisone/prednisolone as per standard medical care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Adult Participants With gMG Who Either: Discontinue Oral Corticosteroids (OCS) or Reduce Their Daily OCS Dosage ≤ 5 mg/day and Maintain this Status for ≥ 4 Weeks Without Clinical Deterioration of gMGTime frame: Up to approximately 32 weeks
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Schaumburg, Illinois · Not yet recruiting
Research Site
Neptune City, New Jersey · Not yet recruiting
Research Site
Raleigh, North Carolina · Recruiting
Research Site
Knoxville, Tennessee · Not yet recruiting
Research Site
Bochum, Germany · Not yet recruiting
Research Site
Milan, Italy · Not yet recruiting
Research Site
Naples, Italy · Not yet recruiting
Research Site
Rome, Italy · Not yet recruiting
Research Site
Ibaraki, Japan · Not yet recruiting
Research Site
Kitakyushu-shi, Japan · Not yet recruiting
Research Site
Kumamoto, Japan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.